Although the prognostic value of XAF1 in ccRCC appears to be limited, its predictive value remains to be determined, especially in patients with metastatic disease undergoing novel combination therapies of targeted agents with Interferon-alpha. This evidence concerns the gene XAF1 and nonpapillary renal cell carcinoma.